Drug intelligence / Profile preview

H5N1 vaccine + AS03

Development stage
Unknown
Lead developer
National Institute of Allergy and Infectious Diseases
Modality
Vaccines & Immunotherapeutics
Administration
Intramuscular
01

Overview

H5N1 vaccine + AS03 is an investigational avian influenza vaccine combination consisting of an H5N1 influenza antigen and the AS03 adjuvant system. AS03 is an oil-in-water emulsion adjuvant composed of squalene, DL-alpha-tocopherol, and polysorbate 80, designed to enhance the immune response to the vaccine antigen. This enhancement typically allows for dose-sparing (using less antigen per dose) and may improve cross-reactivity against different viral strains. The National Institute of Allergy and Infectious Diseases (NIAID) has sponsored clinical studies, including Phase 1/2 trials, to characterize the innate immune responses to this adjuvanted formulation compared to unadjuvanted versions in healthy adults. The vaccine is primarily intended to provide protection against highly pathogenic avian influenza (HPAI) H5N1 strains, which pose a significant pandemic threat.

Other names
AS03-adjuvanted H5N1 influenza vaccineAS-03-adjuvanted H5N1 influenza vaccineAS 03-adjuvanted H5N1 influenza vaccineH5N1 influenza vaccine plus AS03 adjuvantH-5N1 influenza vaccine plus AS03 adjuvantH 5N1 influenza vaccine plus AS03 adjuvantbird flu vaccine with AS03
02

Targets

HA (Hemagglutinin)

Beyond the preview

Go deeper on H5N1 vaccine + AS03.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on H5N1 vaccine + AS03.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call